Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 9/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.47 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927430 | 0.94 | GPR34 (0.47) | GPR34PTPN1ITGB1ITGA4ITGB7 | |
| SCHEMBL5926815 | 0.91 | GPR34 (0.55) | GPR34PTPN1GPR132KIFC1KCNA3 | |
| SCHEMBL5926964 | 0.91 | GPR34 (0.55) | GPR34PTPN1GPR132KIFC1KCNA3 | |
| SCHEMBL5926977 | 0.90 | FFAR1 (0.45) | GPR34KIFC1PPARGITGB1ITGA4 | |
| SCHEMBL5927134 | 0.88 | KCNA3 (0.44) | GPR34KCNA3 | |
| SCHEMBL5927210 | 0.88 | ITGA4 (0.45) | GPR34KIFC1ITGB1ITGA4ITGB7 | |
| SCHEMBL3993018 | 0.87 | GPR132 (0.59) | GPR34PTPN1GPR132KIFC1 | |
| SCHEMBL5926298 | 0.86 | ITGA4 (0.47) | GPR34ITGB1ITGA4ITGB7 | |
| SCHEMBL5927167 | 0.86 | GPR132 (0.51) | GPR34PTPN1GPR132PPARG | |
| SCHEMBL5926541 | 0.86 | KIFC1 (0.48) | GPR34PTPN1GPR132KIFC1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | GPR34 4272/4885PTPN1 2517/4885GPR132 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.